No headlines found.
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
Business Wire (Wed, 24-Jul 4:05 PM ET)
Business Wire (Thu, 18-Jul 9:04 AM ET)
Business Wire (Tue, 18-Jun 9:04 AM ET)
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 17-May 4:05 PM ET)
Business Wire (Wed, 15-May 9:05 AM ET)
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Business Wire (Thu, 9-May 4:58 PM ET)
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
Business Wire (Wed, 8-May 4:05 PM ET)
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
Business Wire (Mon, 29-Apr 4:16 PM ET)
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Acadia Pharmaceuticals trades on the NASDAQ stock market under the symbol ACAD.
As of July 26, 2024, ACAD stock price climbed to $19.14 with 2,230,203 million shares trading.
ACAD has a beta of 1.15, meaning it tends to be more sensitive to market movements. ACAD has a correlation of 0.07 to the broad based SPY ETF.
ACAD has a market cap of $3.16 billion. This is considered a Mid Cap stock.
Last quarter Acadia Pharmaceuticals reported $206 million in Revenue and $.10 earnings per share. This fell short of revenue expectation by $-3 million and exceeded earnings estimates by $.05.
In the last 3 years, ACAD stock traded as high as $33.99 and as low as $12.24.
The top ETF exchange traded funds that ACAD belongs to (by Net Assets): VTI, IWM, XBI, VB, FBT.
ACAD stock has underperformed the market in the last year with a return of -35.3%, while SPY returned +21.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ACAD shares. However, ACAD has outperformed the market in the last 3 month and 2 week periods, returning +17.4% and +8.4%, while SPY returned +8.5% and -2.2%, respectively. This indicates ACAD has been having a stronger performance recently.
ACAD support price is $18.10 and resistance is $19.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACAD stock will trade within this expected range on the day.